Compare Gap Inc (GAP) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Revvity Inc — how do they compare? Gap Inc trades at $20.17 (market cap $7.55B), while Revvity Inc trades at $116.16 (market cap $12.91B). The key difference: Revvity Inc is the larger of the two by market cap, and Gap Inc pays the higher dividend (3.34%). Which is the better fit depends on your goals.
| GAP | RVTY | |
|---|---|---|
Market Cap | $7.55B | $12.91B |
Sector | Consumer Cyclical | Technology |
52-Week High | $29.13 | $117.75 |
52-Week Low | $18.35 | $82.26 |
Enterprise Value | $10.63B | $15.23B |
Dividend Yield | 3.34% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $21.51, up 5.08% today, showing strong momentum amid a bullish technical outlook. The stock presents compelling value with a P/E of 8.32 and P/S of 0.52, well below industry averages. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $0.38 exceeding estimates. Revenue growth has stabilized at $15.1B for 2025, while net income margin improved to 5.59%. The company maintains solid cash flow generation with $464M net cash flow in 2025.
Gap offers attractive valuation upside with a consensus price target of $26.09 (21% potential). However, risks include ongoing investigations by Pomerantz Law Firm and competitive pressures in retail. The turnaround story appears credible with nine consecutive positive comps, but execution risks remain. Current technical indicators suggest the stock is approaching overbought territory with RSI above 70.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
